Skip directly to site content Skip directly to search


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





The National TB Indicators Project (NTIP) Fact Sheet										Related Pages
										NTIP_Project
**What are the national TB Program Objectives?**
The National TB Program Objectives reflect national TB prevention and control priorities in the United States. A comprehensive list of the National TB Program Objectives and performance targets is available on the Centers for Disease Control and Prevention (CDC) website at https://www.cdc.gov/tb/programs/evaluation/indicators/default.htm
**What is the National Tuberculosis Indicators Project (NTIP)?**
NTIP is a web-based performance-monitoring tool. Indicators are measures developed to assess program progress toward the National TB Program Objectives agreed upon by CDC and the federally funded TB programs. NTIP provides TB program officials with indicator reports describing their program’s progress based on routine surveillance data collected and reported to the CDC Division of Tuberculosis Elimination (DTBE). Using NTIP, CDC consultants and TB program officials prioritize prevention and control activities, as well as program evaluation activities.
**Why was NTIP undertaken?**
Program evaluation is an essential component of an effective public health program. Since 2005, CDC has included program evaluation as a core requirement of the Tuberculosis Elimination and Laboratory Cooperative Agreement. NTIP was developed to facilitate the use of existing data to help program staff prioritize activities, monitor progress, and focus program improvement efforts.
**How does NTIP impact TB control programs?**
NTIP uses a standardized method for calculating indicators associated with the national TB program objectives and for tracking program progress across sites and over time. This enables CDC and TB programs to assess the impact of TB control efforts at state and local levels.
**How is NTIP integrated into the cooperative agreement reporting process?**
The Tuberculosis Elimination and Laboratory Cooperative Agreement uses the national TB program objectives as a framework for monitoring and managing programmatic activities for TB control and prevention. NTIP provides TB programs with reports of their progress on achieving these performance objectives using data collected and reported to CDC through electronic data reporting systems. TB program officials then use NTIP to track and report progress toward achieving national objectives as part of the cooperative agreement reporting requirements (i.e., annual progress reports), as well as toward preparing their applications for continued funding.
CDC consultants monitor individual program progress using NTIP and work with TB program officials and staff to identify areas needing technical assistance and further examination.
**How can NTIP assist with program evaluation?**
NTIP is a monitoring system using standardized indicators and calculations to track progress toward national TB program objectives. Program evaluation is the systematic examination of programmatic processes to understand factors that have contributed to program outcomes. TB program staff can use NTIP reports to identify areas for further examination using program evaluation methodologies. Findings from program evaluation studies can then be used to formulate strategies to improve program practices.
**Who has access to NTIP? What do TB program staff need to do to use this system?**
Access to NTIP is granted to state and local TB program staff by the designated TB system administrator(s) for their programs. Program staff can only be granted access to NTIP data for the programs or jurisdictions they work in. Staff who need access to NTIP should contact their program TB System Administrator and the CDC’s DTBE Technical Support Helpdesk via DTBESupport@cdc.gov for assistance.
NTIP reports are also available for some program areas that are not direct recipients of TB cooperative agreement funding. State program officials may request the development of additional reports for monitoring and working with their local jurisdictions.
**What are the data sources for NTIP?**
NTIP uses routine data reported to CDC via the Report of Verified Case of Tuberculosis (RVCT), the Aggregate Reports for Tuberculosis Program Evaluation (ARPE) on contacts of TB cases, the Electronic Disease Notification (EDN) system for the follow-up examination of immigrants and refugees with a B notification, and the TB Genotyping Information System (TB GIMS), as well as population data from the U.S. Census Bureau.
**How often are data updated?**
NTIP is updated daily with data submitted to and received by CDC. This dynamic system allows program staff to generate reports using the most up-to-date data. Reports can also be generated using data frozen at the end of each year. Data generated using frozen data correspond to those reported in the CDC Annual TB Surveillance Report.
Program staff members are encouraged to review NTIP data for their program on a routine basis to ensure data submitted to CDC are accurate and complete. Individual case data are available to program staff for cross matching and validation with local registries.
**How can NTIP help with the Aggregate Reports for Tuberculosis Program Evaluation (ARPE)?**
The NTIP system hosts the electronic data entry and reporting of outcomes for TB contact investigations collected in the Aggregate Reports for Tuberculosis Program Evaluation (ARPE). State and local TB program staff should use NTIP to submit ARPE reports to CDC. Staff who need access to the ARPE functionality in NTIP should contact their program TB System Administrator and the CDC’s DTBE Technical Support Helpdesk via DTBESupport@cdc.gov for assistance.
**What training or support is currently available on NTIP?**
CDC staff are available to assist in using and interpreting NTIP reports. Technical assistance for accessing and navigating the NTIP system and understanding and resolving data questions is also provided by CDC’s DTBE Technical Support Helpdesk by emailing DTBESupport@cdc.gov. Additionally, training on NTIP for new program management staff is available through the CDC TB Program Managers’ Course.Additional ResourcesCDC Aggregate Report for Tuberculosis Program Evaluation: Training Manual and User’s Guide, 2005
ARPE Follow-Up Treatment of Contacts of Tuberculosis Patients Form & Updated Guidance [PDF – 117 KB]
ARPE Targeted Testing and Treatment for Latent Tuberculosis Infection Form & Updated Guidance [PDF – 250 KB]
CDC Disease Surveillance Among Newly Arriving Refugees and Immigrants — Electronic Disease Notification System, United States, 2009. MMWR, November 15, 2013 / 62(SS07);1-20
CDC National TB Indicators Project (NTIP) Companion for Data Managers, 2015
CDC National TB Indicators Project (NTIP) User Guide, 2015
CDC Report of Verified Case of Tuberculosis (RVCT): Instruction Manual, 2020
CDC TB Genotyping Information Management System (TB GIMS)
The Electronic Disease Notification system (EDN)
					View Page In:PDF [376K]		
					
						Page last reviewed:  June 30, 2022					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue